NasdaqGM:XNCRBiotechs
Will Xencor’s (XNCR) XmAb819 Data Update Reveal New Strengths in Its Oncology Pipeline?
Xencor recently announced it will host a conference call and webcast to discuss initial results from its Phase 1 dose-escalation study of XmAb819, a bispecific antibody for advanced clear cell renal cell carcinoma, following a presentation at a major cancer conference in Boston on October 24.
Early data from XmAb819, which targets ENPP3 in kidney cancers, marks a potential milestone for Xencor’s portfolio of engineered antibody therapies.
We'll review how the anticipated clinical data...